15389-33-0

Usage

Uses

Used in Pharmaceutical Industry:
4,4,4-TRIFLUORO-1-PHENANTHREN-2-YL-BUTANE-1,3-DIONE is used as a synthetic intermediate for the development of new pharmaceuticals. Its unique structure and reactivity make it a valuable component in the creation of novel drug molecules with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 4,4,4-TRIFLUORO-1-PHENANTHREN-2-YL-BUTANE-1,3-DIONE serves as a key building block for the synthesis of new agrochemicals. Its properties contribute to the development of innovative compounds with applications in crop protection and pest control.
Used in Organic Synthesis:
4,4,4-TRIFLUORO-1-PHENANTHREN-2-YL-BUTANE-1,3-DIONE is used as a versatile building block in organic synthesis. Its unique structure allows for the creation of a wide range of organic compounds with various applications in research and industry.
Used in Material Science:
In the field of material science, 4,4,4-TRIFLUORO-1-PHENANTHREN-2-YL-BUTANE-1,3-DIONE is utilized for the synthesis of new organic materials. Its properties can contribute to the development of advanced materials with specific properties for use in various applications.
It is crucial to handle 4,4,4-TRIFLUORO-1-PHENANTHREN-2-YL-BUTANE-1,3-DIONE with proper safety precautions due to the potential hazards associated with fluorinated compounds.

Upstream product

• 383-63-1 ethyl trifluoroacetate, 
• 5960-69-0 2-acetylphenanthrene 

Downstream Products

• 1100051-52-2 C₂₄H₁₄F₃N₃O₂ 
• 1092540-88-9 C₃₁H₂₇F₃N₄O₃ 
• 1148046-98-3 C₃₀H₂₈F₃N₅O 
• 1148046-97-2 C₃₀H₂₈F₃N₅O 
• 1148046-99-4 C₂₇H₂₁F₃N₄O 
• 1148047-04-4 (N-{4-[5-(phenanthren-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}sulfuric diamide) 
• 742112-33-0 2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}acetamide 

Relevant academic research and scientific papers

Development of novel antibacterial agents against methicillin-resistant Staphylococcus aureus

Methicillin-resistant Staphylococcus aureus (MRSA) poses a serious threat to public health because of its resistance to multiple antibiotics most commonly used to treat infection. In this study, we report the unique ability of the cyclooxygenase-2 (COX-2) inhibitor celecoxib to kill Staphylococcus aureus and MRSA with modest potency. We hypothesize that the anti-Staphylococcus activity of celecoxib could be pharmacologically exploited to develop novel anti-MRSA agents with a distinct mechanism. Examination of an in-house, celecoxib-based focused compound library in conjunction with structural modifications led to the identification of compound 46 as the lead agent with high antibacterial potency against a panel of Staphylococcus pathogens and different strains of MRSA. Moreover, this killing effect is bacteria-specific, as human cancer cells are resistant to 46. In addition, a single intraperitoneal administration of compound 46 at 30 mg/kg improved the survival of MRSA-infected C57BL/6 mice. In light of its high potency in eradicating MRSA in vitro and its in vivo activity, compound 46 and its analogues warrant continued preclinical development as a potential therapeutic intervention against MRSA.

Compounds and methods for inducing apoptosis in proliferating cells

Compounds useful for inducing apoptosis in proliferative cells, particularly cancer cells, including but not limited to prostate cancer, leukemia, non-smalll cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, bladder cancer, lymphoma, and breast cancer. These compounds are particularly useful in the treatment of androgen-independent cancers, including hormone-refractory prostate cancer. Further provided are methods of treating cancer in a subject in need of such treatment using the compounds of the present invention. Further provided are methods for using the compounds of the present invention to treat, inhibit, or delay the onset of cancer in a subject. Further provided are methods of inducing apoptosis in rapidly proliferating cells, particularly, though not necessarily cancer cells, using the compounds of the present invention.